Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00672061 · ClinicalTrials.gov registry record · Phase 2
Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea
A Phase 2 study of Sleep Apnea, Obstructive, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 5
- Study locations
NCT00672061: Completed Phase 2 study of Sleep Apnea, Obstructive, sponsored by Takeda.
NCT00672061 is a Phase 2 study of Sleep Apnea, Obstructive that has completed, run by Takeda. The registered enrollment target is 26 participants, below the 262-participant average among 45 other Sleep Apnea, Obstructive trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00672061, a Phase 2 study of Sleep Apnea, Obstructive, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to assess the safety of ramelteon, once daily (QD), in individuals with obstructive sleep apnea.
Conditions Studied
Interventions
- DRUG Ramelteon or Placebo
Study Locations (5)
California
- - Palm Springs
- - Santa Monica
Alabama
- - Birmingham
Florida
- - Winter Park
Ohio
- - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2003-07 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
What the finished NCT00672061 record still lists
NCT00672061 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 262-participant average among 45 other Sleep Apnea, Obstructive trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Sleep Apnea, Obstructive appearing as the primary indexed condition, and to 1 intervention - of which Ramelteon or Placebo is the first listed.
NCT00672061 lists 5 locations in 4 states (California, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT00672061 about?
NCT00672061 is a clinical study titled "Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea". The purpose of this study is to assess the safety of ramelteon, once daily (QD), in individuals with obstructive sleep apnea.
What is the current status of trial NCT00672061?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2003-07. Estimated completion is 2003-12.
What conditions does trial NCT00672061 study?
This clinical trial studies the following conditions: Sleep Apnea, Obstructive.
What interventions are being tested in trial NCT00672061?
The interventions under investigation include: Ramelteon or Placebo (DRUG).
Who is sponsoring clinical trial NCT00672061?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00672061 being conducted?
This trial has 5 study locations across Alabama, California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sleep Apnea, Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00672061's enrollment target sits among peer trials
26 36th of 45 higher than 9 of 45 other Sleep Apnea, Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sleep Apnea, Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Do Endotypes Predict Response and Sequelae in OSA Patients
RECRUITING · Phase 2
-
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
RECRUITING · Phase 2
-
Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B
COMPLETED · Phase 2
-
Nasal vs Oral Breathing in Drug Induced Sleep vs Natural Sleep
RECRUITING
-
The PREDICTOR Study: Assessing Diagnostic Predictors of Airway Collapse in Patients With Obstructive Sleep Apnea
RECRUITING · NA
-
Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia